Evidence map›Paper›PMID 29133554›Full record

ArticleAntimicrobial agents and chemotherapy2018

What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.

Jan Heyckendorf, Sönke Andres, Claudio U Köser, Ioana D Olaru, Thomas Schön, Erik Sturegård, Patrick Beckert, Viola Schleusener, Thomas A Kohl, Doris Hillemann and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 4 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 4 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Open-access genomic drug resistance prediction tools forJournal of clinical microbiology · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Mixed infections and heteroresistance ofEmerging microbes & infections · 2025
    Article
  13. Article
  14. Rapid detection of rifampin resistance inMicrobiology spectrum · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Multidrug-resistant tuberculosis.Nature reviews. Disease primers · 2024
    Review
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 4 countries.

Jan Heyckendorf *Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
Sönke Andres *Division of Mycobacteriology (National Tuberculosis Reference Laboratory), Research Center Borstel, Borstel, Germany.
Claudio U Köser *Department of Genetics, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0002-0232-846X
Ioana D OlaruDivision of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.ORCID 0000-0003-3392-9257
Thomas SchönDepartment of Infectious Diseases and Clinical Microbiology, Kalmar County Hospital, Kalmar, Sweden.
Erik SturegårdClinical Microbiology, Department of Translational Medicine, Lund University, Malmö, Sweden.
Patrick BeckertGerman Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel, Borstel, Germany.
Viola SchleusenerDivision of Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
Thomas A KohlGerman Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel, Borstel, Germany.
Doris HillemannDivision of Mycobacteriology (National Tuberculosis Reference Laboratory), Research Center Borstel, Borstel, Germany.
Danesh MoradigaravandWellcome Trust Sanger Institute, Hinxton, United Kingdom.
Julian ParkhillWellcome Trust Sanger Institute, Hinxton, United Kingdom.ORCID 0000-0002-7069-5958
Sharon J PeacockDepartment of Genetics, University of Cambridge, Cambridge, United Kingdom.
Stefan NiemannGerman Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel, Borstel, Germany sniemann@fz-borstel.de clange@fz-borstel.de.
Christoph LangeDivision of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany sniemann@fz-borstel.de clange@fz-borstel.de.ORCID 0000-0002-9691-4741
Matthias MerkerGerman Center for Infection Research (DZIF), Partner site Hamburg-Lübeck-Borstel, Borstel, Germany.
German Center for Infection Research · DEResearch Center Borstel - Leibniz Lung Center · DEUniversity of Cambridge · GBWellcome Sanger Institute · GBLinköping University · SELund University · SEUniversity of Namibia · NA

Funding

Wellcome TrustWellcome Trust WT098600
6 · The paper itself

Abstract

Rapid and accurate drug susceptibility testing (DST) is essential for the treatment of multi- and extensively drug-resistant tuberculosis (M/XDR-TB). We compared the utility of genotypic DST assays with phenotypic DST (pDST) using Bactec 960 MGIT or Löwenstein-Jensen to construct M/XDR-TB treatment regimens for a cohort of 25 consecutive M/XDR-TB patients and 15 possible anti-TB drugs. Genotypic DST results from Cepheid GeneXpert MTB/RIF (Xpert) and line probe assays (LPAs; Hain GenoType MTBDR

Indexed as

Genome, BacterialAntitubercular AgentsBacterial Typing TechniquesCohort StudiesDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisGenotypeHumansKanamycinLevofloxacinMicrobial Sensitivity TestsMoxifloxacinMycobacterium tuberculosisPhenotypeRifampinTuberculosis, Multidrug-ResistantAntitubercular AgentsKanamycinLevofloxacinMoxifloxacinRifampinantibiotic resistancemolecular geneticsMycobacterium tuberculosis

Identifiers

PMID29133554
PMCPMC5786814
OpenAlexW2768676941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.